Apira Science’s iGrow Becomes First Hair Growth Device Cleared by China Food and Drug Administration (CFDA)

BOCA RATON, Fla.--()--Apira Science, Inc. continues its global expansion, receiving clearance for the iGrow Hair Growth System in China. The iGrow is now the only hair growth device to receive clearance from the China Food and Drug Administration (CFDA) and the only device to have both U.S. FDA and CFDA clearance. Apira will distribute the iGrow in China in partnership with China Central Pharmaceuticals, one of the nation’s largest privately held pharmaceutical companies, which has been Apira’s exclusive distributor in the country since 2013.

“This clearance gives Apira access to China’s rapidly growing market for hair loss treatments, and positions iGrow as the only proven hair loss device available to Chinese consumers,” said Jeff Braile, president of Apira Science. “We look forward to working with China Central Pharmaceuticals to make this clinically proven low-level light therapy (LLLT) treatment available to those individuals in this country suffering from hereditary hair loss.”

“Given China’s enormous population and need for hair loss treatments, the availability of the iGrow Hair Growth System to Chinese hospitals and medical centers will be favorably received,” said Teng Ma, president of China Central Pharmaceuticals. “Our collaboration demonstrates the true power of partnership.”

The CFDA clearance elevates the iGrow within the 33.6 billion yuan ($5.5 billion) Chinese hair care market, in which sales of Western hair-loss treatments grew 90 percent from 2007 to 2012. The announcement also comes on the heels of clearances throughout Asia, including South Korea, Thailand, and Singapore. China is the latest addition to the dozens of countries where iGrow is already approved, including the United States, Canada, Mexico, Hong Kong, and India. iGrow is also available in all 28 European Union nations, Turkey, and the United Kingdom.

The iGrow Hair Growth System is an innovative, safe, and effective hands-free LLLT hair growth device cleared by the FDA for at-home use. In clinical studies, the iGrow’s patented red light technology, which consists of a highly productive combination of red laser and LED diodes, increased hair growth 37 percent after 16 weeks of therapy, and nearly doubled total hair growth 10 weeks faster than hand-held laser combs and brushes.

For more information on the iGrow Hair Growth System, visit www.igrowlaser.com.

About Apira Science, Inc.

Apira Science, Inc. has pioneered low-level light therapy (LLLT) for over a decade. Its iGrow Hair Growth Platform draws on its expertise and innovations in the application of LLLT to deliver a simple, safe, and effective hair growth treatment.

Contacts

Press contact:
Gregory FCA
Denise DiMeglio
610-228-2102
denise@gregoryfca.com

Release Summary

Apira Science’s iGrow Becomes First Hair Growth Device Cleared by China Food and Drug Administration (CFDA)

#Hashtags

Social Media Profiles

Contacts

Press contact:
Gregory FCA
Denise DiMeglio
610-228-2102
denise@gregoryfca.com